NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/22/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization389.43 mln
Float6.00 mln
Earnings Date08/27/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
35.80
Transformational upside
Relative Strength
2
/ 100
Severely lagging
Debt / Equity
0.10
Very low leverage
ROE
-56.39
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Artiva Biotherapeutics is a San Diego-based clinical-stage company, founded in 2019, that develops treatments using natural killer cells ? a type of immune cell the body uses to fight disease. Its main therapy, AlloNK, is a ready-to-use cell treatment being studied for a range of autoimmune conditions as well as certain blood cancers. The company is also advancing two additional cell-based treatments aimed at solid tumors, including breast, gastric, and bladder cancers, and at other blood-related cancers.
